Dose–Response Effects of Survodutide vs Semaglutide on HbA1c Level and Bodyweight Reductions in People With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Diabetologia 2024 Mar 01;67(3)470-482, M Blüher, J Rosenstock, J Hoefler, R Manuel, AM HennigeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.